Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Find studies

Showing 1,301–1,325 of 1,328 studies of type cross-sectional study (page 53 of 54) · 27,780 in the whole library · How the 0–100 score works

Download bibliography of the first 500 of these studies, in this order: BibTeX (.bib) · RIS (.ris)

This list as a page: Cross-sectional study in the library →

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

Family physicians' attitudes toward people with dementia and their association with empathy

⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. Research Square 2026-10-14

Family physicians' empathy levels were independently associated with general, supportive, and accepting attitudes toward people with dementia, but not with exclusionary attitudes. 5 key findings →

Design: cross-sectional Participants: 412 Evidence: low

Data collection started on June 3, 2026, and is planned to close on June 30, 2026. 2 key findings →

Design: cross-sectional Evidence: low

Polypharmacy and PIMs are highly prevalent in end-of-life elderly cancer patients. 3 key findings →

Design: cross-sectional Participants: 183 Evidence: low

Prevalence of dementia and mild cognitive impairment in Morocco: A population-based study

⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. Research Square 2026-10-22

This nationwide study provides epidemiological data on dementia and MCI among adults aged ≥ 60 years across all 12 administrative regions of Morocco. 1 key finding →

Design: cross-sectional Participants: 1,662 Evidence: low

This study reports the prevalence of CF among elderly hypertensive residents of a community in Inner Mongolia. 5 key findings →

Design: cross-sectional Evidence: low

Curation of Mini Mental State Examination (MMSE) Scores in the VA Million Veteran Program (MVP): Applications for Cognitive Aging Research

⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. medRxiv 2026-07-16

This study demonstrated MMSE scores can be systematically extracted and curated from the VA EHR. 3 key findings →

Design: cross-sectional Participants: 49,555 Evidence: moderate

Determinants of fractal motor activity regulation: insights from a large community-dwelling multi-ethnic population

⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. Research Square 2026-07-06

We found opposite effects of age on FMAR at both short and long time scales, respectively (ßAge=0.014, 95% C.I. [0.009,0.019] and ßAge=-0.015, 95% C.I. [-0.026,-0.005]), as well as differences between women and men at long time scales (ßSexMen=+0.028, 95% C.I. [0.012,0.044]). 5 key findings →

Design: cross-sectional Evidence: moderate

Prevalence of epilepsy and young-onset dementia in adults with intellectual disability: Contrasting Down syndrome and autism diagnoses

⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. PsyArXiv 2026-06-15

Higher prevalence was observed in the ID group relative to the general population for epilepsy, young-onset ADRD, and their comorbidity. 5 key findings →

Design: cross-sectional Participants: 847,430 Evidence: low

Risk factors for Dementia Public Stigma in Zhejiang Province, China: A Cross-Sectional Study

⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. Research Square 2026-09-07

Dementia public stigma was associated with education, dementia knowledge, media exposure, chronic diseases, and contact experience with people living with dementia. 5 key findings →

Design: cross-sectional Participants: 3,055 Evidence: low

Serum brain-derived p-tau 217 and SV2A Reduce Peripheral Interference in Alzheimer’s Disease: A Multicohort Study

⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. medRxiv 2026-07-30

Our findings suggest that serum brain-derived p-tau 217 and SV2A are more specific diagnostic biomarkers for reflecting brain damage and may not be disturbed by peripheral damage for AD patients. 5 key findings →

Design: cross-sectional Participants: 1,198 Evidence: moderate

Functional–behavioral subtypes can be identified in hospitalized AD patients, supporting multidimensional risk stratification and individualized care planning. 2 key findings →

Design: cross-sectional Participants: 118 Evidence: low

Wearable devices may facilitate the measurement and treatment of specific BPSD, as well as reduce caregiver burden. 2 key findings →

Design: cross-sectional Participants: 20 Evidence: moderate

Spoken Recall Reveals Lexical and Mnemonic Function Differences in Temporal Lobe Epilepsy Patients

⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. bioRxiv 2026-08-25

We examined whether natural language processing and acoustic analysis of spoken biographical recall could identify lexical and temporal speech features associated with language and memory performance in TLE. 5 key findings →

Design: cross-sectional Evidence: moderate

Vocal acoustic biomarkers predict amyloid positivity in non-demented individuals

⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. Research Square 2026-09-11

Amyloid-β deposition begins in the earliest preclinical stages of Alzheimer's disease, long before cognitive decline is detectable by standard clinical assessments, which are often limited by ceiling effects and create a need for non-invasive, scalable markers. 1 key finding →

Design: cross-sectional Evidence: low

In cognitively unimpaired older adults, associations between sleep disturbances and psycho-affective symptoms differ according to Aβ status. 2 key findings →

Design: cross-sectional Participants: 131 Evidence: moderate

Cognitive Impairment during Migraine Attacks: An Analysis from the American Registry for Migraine Research (ARMR)

⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. Research Square 2026-10-18

Among 1,231 patients (87.2% women; mean age 46.0 ± 13.7 years; 71.5% chronic migraine), 1,175/1,231 (95.5%) endorsed cognitive symptoms, with a mean Mig-SCog total score of 8.2 ± 4.8. 5 key findings →

Design: cross-sectional Participants: 661 Evidence: moderate

Multilingualism and ageing: Cognitive and affective trajectories in the Australian Longitudinal Study of Ageing

⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. Research Square 2026-10-06

This study aimed to address these limitations by examining whether multilingual experience is associated with longitudinal ageing trajectories across objective and subjective measures spanning cognitive, affective, linguistic, and non-linguistic domains. 5 key findings →

Design: cross-sectional Participants: 193 Evidence: moderate

In this cross-sectional sample, mobility showed a progressively stronger statistical indirect association with the cognition-ADL relationship as cognitive impairment deepened. 3 key findings →

Design: cross-sectional Participants: 1,234 Evidence: moderate

Selective vulnerability of human basal forebrain subsystems in ageing and neuropsychiatric disorders

⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. medRxiv 2026-10-15

These findings identify an anatomically specific age-related profile of the human BF, with structural vulnerability manifest and pre-diagnostic neurological disorders, which is not substantially explained by common inherited risk. 2 key findings →

Design: cross-sectional Evidence: moderate

Digital and Health Literacy Are Associated with Health-Related Quality of Life Across Cognitive Impairment Stages in Older Adults

⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. Research Square 2026-09-04

Digital literacy is a meaningful predictor of HRQoL in older adults with intact or mildly impaired cognition, underscoring its potential as an intervention target in digital health strategies. 5 key findings →

Design: cross-sectional Participants: 121 Evidence: low

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 27,780 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,780 records, built mostly from automated pulls of Europe PMC (61.1% of the library) and OpenAlex (18.3%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed